<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737319</url>
  </required_header>
  <id_info>
    <org_study_id>IDPC3851</org_study_id>
    <nct_id>NCT02737319</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).</brief_title>
  <acronym>CLEAR-CIN</acronym>
  <official_title>A Randomized Trial of Rosuvastatin in Elective Percutaneous Coronary Intervention to Prevent Contrast-induced (CLEAR-CIN).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Dante Pazzanese de Cardiologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention
      of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with stable coronary artery disease already taking chronic statin undergoing
      elective angioplasty are at risk for contrast-medium-induced nephropathy because there are
      specified risk factors as age more than 75 years, chronic renal insufficiency, diabetes, use
      of contrast and the lack of effective prophylaxis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contrast induce nephropathy defined by serum creatinine increase more than 0.3mg/dl or 50% higher than baseline</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum creatinine increase more than 0.3mg/dl or 50% higher than baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite end-point ( all cause of death; acute renal failure and no-fatal mayocardial infarctio.</measure>
    <time_frame>48 hours</time_frame>
    <description>Death, myocardial infarction or kidney insufficiency</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">493</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg of Rosuvastatin up to 6 hours before elective percutaneous coronary intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Use of standard therapy in elective angioplasty.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>40 mg of rosuvastatin before angioplasty</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic statin use

          -  positive stress test findings (electrocardiography, nuclear imaging, or stress
             echocardiography

          -  elective angioplasty.

        Exclusion Criteria:

          -  non-statin therapy

          -  any presentation of ACS within 24 hours before the time of randomization

          -  current use of potent CYP3A4 inhibitors, including azole antifungals, protease
             inhibitors, macrolide antibiotics, and cyclosporine

          -  renal replacement therapy, a history of kidney transplant, pregnant and with renal
             failure (serum creatinine &gt; 3.0 mg/dl).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kleber Bomfim A Martins, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Date Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Kleber Bomfim Araujo Martins</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Contrast,nephropathy, angioplasty, stable coronary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

